Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Sanofi SA (NASDAQ:SNY) agreed to make a $27 million strategic investment in Ventyx Biosciences Inc (NASDAQ:VTYX). “We look ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.

Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...